News Releases

News Releases

April 8, 2021
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at
March 18, 2021
$262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024 Ron Cooper appointed to Board of Directors Company remains on track to begin IND-enabling studies for hemophilia A in 2021 CAMBRIDGE,
February 18, 2021
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021.
January 11, 2021
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its public offering of 9,200,000 shares of its common stock at a public offering price of $24.50 per
January 6, 2021
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per
January 5, 2021
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan.
January 4, 2021
Data confirm delivery of closed-ended DNA to the liver via novel, cell-targeted lipid nanoparticles Well tolerated at all dose levels in mice and non-human primates Company on track to select development candidate for hemophilia A and begin IND-enabling studies this year, submit IND in 2022 Webcast
cross